The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Identifieur interne : 000117 ( Ncbi/Merge ); précédent : 000116; suivant : 000118The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Auteurs : B. Henry [Royaume-Uni] ; S H Fox ; D. Peggs ; A R Crossman ; J M BrotchieSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1999.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacokinetics), Adrenergic Antagonists (pharmacology), Adrenergic Antagonists (therapeutic use), Animals, Antiparkinson Agents (metabolism), Brain (metabolism), Callithrix, Disease Models, Animal, Disease Progression, Dose-Response Relationship, Drug, Drug Synergism, Dyskinesias (drug therapy), Female, Idazoxan (pharmacology), Idazoxan (therapeutic use), Levodopa (metabolism), Male, Receptors, Adrenergic, alpha-2 (drug effects), Time Factors, Yohimbine (pharmacology), Yohimbine (therapeutic use).
- MESH :
- chemical , drug effects : Receptors, Adrenergic, alpha-2.
- chemical , metabolism : Antiparkinson Agents, Levodopa.
- chemical , pharmacokinetics : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemical , pharmacology : Adrenergic Antagonists, Idazoxan, Yohimbine.
- chemical , therapeutic use : Adrenergic Antagonists, Idazoxan, Yohimbine.
- drug therapy : Dyskinesias.
- metabolism : Brain.
- Animals, Callithrix, Disease Models, Animal, Disease Progression, Dose-Response Relationship, Drug, Drug Synergism, Female, Male, Time Factors.
Abstract
Dopamine replacement therapy in patients with Parkinson's disease is plagued by the emergence of abnormal involuntary movements known as L-dopa-induced dyskinesias. It has been demonstrated that yohimbine can reduce L-dopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Yohimbine is, among other things, an alpha-adrenergic receptor antagonist. In this study, we demonstrate that the selective and potent alpha2-adrenergic receptor antagonist idazoxan reduces L-dopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. The alpha2-adrenergic receptor antagonists rauwolscine and yohimbine also reduce L-dopa-induced dyskinesia. Furthermore, we demonstrate that coadministration of idazoxan with L-dopa can provide an anti-parkinsonian action more than twice the length of that seen with L-dopa alone. However, idazoxan as a monotherapy displayed no anti-parkinsonian actions. We propose that idazoxan in combination with L-dopa may provide a novel approach to the treatment of Parkinson's disease that will not only reduce the dyskinetic side effects, but extend the anti-parkinsonian actions of L-dopa. Idazoxan, as an adjunct to dopamine replacement, may prove useful in the treatment of parkinsonian patients at all stages of disease progression.
PubMed: 10495035
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004134
- to stream PubMed, to step Curation: 004134
- to stream PubMed, to step Checkpoint: 004092
Links to Exploration step
pubmed:10495035Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.</title>
<author><name sortKey="Henry, B" sort="Henry, B" uniqKey="Henry B" first="B" last="Henry">B. Henry</name>
<affiliation wicri:level="1"><nlm:affiliation>Organon Laboratories Limited, Department of Pharmacology, Lanarkshire, Scotland, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Organon Laboratories Limited, Department of Pharmacology, Lanarkshire, Scotland</wicri:regionArea>
<wicri:noRegion>Scotland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fox, S H" sort="Fox, S H" uniqKey="Fox S" first="S H" last="Fox">S H Fox</name>
</author>
<author><name sortKey="Peggs, D" sort="Peggs, D" uniqKey="Peggs D" first="D" last="Peggs">D. Peggs</name>
</author>
<author><name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A R" last="Crossman">A R Crossman</name>
</author>
<author><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J M" last="Brotchie">J M Brotchie</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10495035</idno>
<idno type="pmid">10495035</idno>
<idno type="wicri:Area/PubMed/Corpus">004134</idno>
<idno type="wicri:Area/PubMed/Curation">004134</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004092</idno>
<idno type="wicri:Area/Ncbi/Merge">000117</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.</title>
<author><name sortKey="Henry, B" sort="Henry, B" uniqKey="Henry B" first="B" last="Henry">B. Henry</name>
<affiliation wicri:level="1"><nlm:affiliation>Organon Laboratories Limited, Department of Pharmacology, Lanarkshire, Scotland, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Organon Laboratories Limited, Department of Pharmacology, Lanarkshire, Scotland</wicri:regionArea>
<wicri:noRegion>Scotland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fox, S H" sort="Fox, S H" uniqKey="Fox S" first="S H" last="Fox">S H Fox</name>
</author>
<author><name sortKey="Peggs, D" sort="Peggs, D" uniqKey="Peggs D" first="D" last="Peggs">D. Peggs</name>
</author>
<author><name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A R" last="Crossman">A R Crossman</name>
</author>
<author><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J M" last="Brotchie">J M Brotchie</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacokinetics)</term>
<term>Adrenergic Antagonists (pharmacology)</term>
<term>Adrenergic Antagonists (therapeutic use)</term>
<term>Animals</term>
<term>Antiparkinson Agents (metabolism)</term>
<term>Brain (metabolism)</term>
<term>Callithrix</term>
<term>Disease Models, Animal</term>
<term>Disease Progression</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Synergism</term>
<term>Dyskinesias (drug therapy)</term>
<term>Female</term>
<term>Idazoxan (pharmacology)</term>
<term>Idazoxan (therapeutic use)</term>
<term>Levodopa (metabolism)</term>
<term>Male</term>
<term>Receptors, Adrenergic, alpha-2 (drug effects)</term>
<term>Time Factors</term>
<term>Yohimbine (pharmacology)</term>
<term>Yohimbine (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Adrenergic, alpha-2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adrenergic Antagonists</term>
<term>Idazoxan</term>
<term>Yohimbine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic Antagonists</term>
<term>Idazoxan</term>
<term>Yohimbine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Callithrix</term>
<term>Disease Models, Animal</term>
<term>Disease Progression</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Synergism</term>
<term>Female</term>
<term>Male</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dopamine replacement therapy in patients with Parkinson's disease is plagued by the emergence of abnormal involuntary movements known as L-dopa-induced dyskinesias. It has been demonstrated that yohimbine can reduce L-dopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Yohimbine is, among other things, an alpha-adrenergic receptor antagonist. In this study, we demonstrate that the selective and potent alpha2-adrenergic receptor antagonist idazoxan reduces L-dopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. The alpha2-adrenergic receptor antagonists rauwolscine and yohimbine also reduce L-dopa-induced dyskinesia. Furthermore, we demonstrate that coadministration of idazoxan with L-dopa can provide an anti-parkinsonian action more than twice the length of that seen with L-dopa alone. However, idazoxan as a monotherapy displayed no anti-parkinsonian actions. We propose that idazoxan in combination with L-dopa may provide a novel approach to the treatment of Parkinson's disease that will not only reduce the dyskinetic side effects, but extend the anti-parkinsonian actions of L-dopa. Idazoxan, as an adjunct to dopamine replacement, may prove useful in the treatment of parkinsonian patients at all stages of disease progression.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">10495035</PMID>
<DateCreated><Year>1999</Year>
<Month>11</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted><Year>1999</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>14</Volume>
<Issue>5</Issue>
<PubDate><Year>1999</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>744-53</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Dopamine replacement therapy in patients with Parkinson's disease is plagued by the emergence of abnormal involuntary movements known as L-dopa-induced dyskinesias. It has been demonstrated that yohimbine can reduce L-dopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Yohimbine is, among other things, an alpha-adrenergic receptor antagonist. In this study, we demonstrate that the selective and potent alpha2-adrenergic receptor antagonist idazoxan reduces L-dopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. The alpha2-adrenergic receptor antagonists rauwolscine and yohimbine also reduce L-dopa-induced dyskinesia. Furthermore, we demonstrate that coadministration of idazoxan with L-dopa can provide an anti-parkinsonian action more than twice the length of that seen with L-dopa alone. However, idazoxan as a monotherapy displayed no anti-parkinsonian actions. We propose that idazoxan in combination with L-dopa may provide a novel approach to the treatment of Parkinson's disease that will not only reduce the dyskinetic side effects, but extend the anti-parkinsonian actions of L-dopa. Idazoxan, as an adjunct to dopamine replacement, may prove useful in the treatment of parkinsonian patients at all stages of disease progression.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henry</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Organon Laboratories Limited, Department of Pharmacology, Lanarkshire, Scotland, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fox</LastName>
<ForeName>S H</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Peggs</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Crossman</LastName>
<ForeName>A R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brotchie</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>UNITED STATES</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018674">Adrenergic Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018341">Receptors, Adrenergic, alpha-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2Y49VWD90Q</RegistryNumber>
<NameOfSubstance UI="D015016">Yohimbine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9P21XSP91P</RegistryNumber>
<NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Y310PA316B</RegistryNumber>
<NameOfSubstance UI="D019329">Idazoxan</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018674">Adrenergic Antagonists</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002144">Callithrix</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D004195">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D020820">Dyskinesias</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019329">Idazoxan</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018341">Receptors, Adrenergic, alpha-2</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015016">Yohimbine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year>
<Month>9</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1999</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1999</Year>
<Month>9</Month>
<Day>24</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10495035</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
</list>
<tree><noCountry><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J M" last="Brotchie">J M Brotchie</name>
<name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A R" last="Crossman">A R Crossman</name>
<name sortKey="Fox, S H" sort="Fox, S H" uniqKey="Fox S" first="S H" last="Fox">S H Fox</name>
<name sortKey="Peggs, D" sort="Peggs, D" uniqKey="Peggs D" first="D" last="Peggs">D. Peggs</name>
</noCountry>
<country name="Royaume-Uni"><noRegion><name sortKey="Henry, B" sort="Henry, B" uniqKey="Henry B" first="B" last="Henry">B. Henry</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000117 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000117 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:10495035 |texte= The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:10495035" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |